Tango Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

Tango Therapeutics

24/03/2023 12:11

* Tango Therapeutics Inc  TNGX.OQ   TNGX.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 27
(estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 12.6% increase in revenue to $6.437 million from $5.72
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Tango Therapeutics
Inc is
for a loss of 35 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tango
Therapeutics Inc is $13.5​, above​ its last closing price
of $4.07. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.32       -0.32      -0.33     Missed  -2.1
 Jun. 30 2022  -0.32       -0.32      -0.28     Beat    13.6
 Mar. 31 2022  -0.28       -0.28      -0.29     Missed  -4.3​
 Dec. 31 2021              -0.27      -0.25     Beat    7.4
 ​​Sep.        -0.28       -0.28      -0.28     Met     0.7
 30 2021                                                
                                                        ​
 This summary was machine generated March 24 at 12:11 GMT.  All
figures in US dollars  unless otherwise stated